$Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR$

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

10.1038/leu.2016.390

Saved in:

Bibliographic Details
Main Authors:	Chng, W-J, Goldschmidt, H, Dimopoulos, MA, Moreau, P, Joshua, D, Palumbo, A, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Feng, S, Aggarwal, S, Hajek, R
Other Authors:	DEAN'S OFFICE (MEDICINE)
Format:	Article
Language:	English
Published:	NATURE PUBLISHING GROUP 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Hematology LOW-DOSE DEXAMETHASONE STEM-CELL TRANSPLANTATION PLUS DEXAMETHASONE INTERGROUPE FRANCOPHONE DELETION 17P LENALIDOMIDE THERAPY ABNORMALITIES POMALIDOMIDE THALIDOMIDE
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/229014
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Internet

https://scholarbank.nus.edu.sg/handle/10635/229014